Intervention against anthrax edema factor (EF)

炭疽水肿因子(EF)的干预

基本信息

  • 批准号:
    6998672
  • 负责人:
  • 金额:
    $ 44.32万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-02-15 至 2006-07-31
  • 项目状态:
    已结题

项目摘要

The bioterrorism-related anthrax in 2001 has shown that anthrax spores can be an effective bioterrorism agent to cause massive disruption and causalities. In the event that anthrax spores are used again, we need all possible therapeutics to protect affected individuals from this terrible bio-warfare agent. Anthrax is caused by the growth of the gram-positive bacteria, Bacillus anthracis and by toxins secreted by anthrax bacteria. Two major anthrax toxins, edema toxin (EdTx) and lethal toxin (LeTx) alter intracellular signaling. Edema factor (EF), the catalytic component of EdTx has calmodulin-activated adenylyl cyclase activity to raise the uncontrolled intracellular cAMP level. The growing evidences suggest that EF is a key virulence factor for anthrax pathogenesis. We have determined the molecular structure of EF alone and EF in complex with calmodulin to show that the interaction of EF with calmodulin is distinctly different from how cellular targets bind to calmodulin. We hypothesize that small molecular weight compound that can specifically bind EF and disrupt the interaction with calmodulin could be exploited for potential therapeutics against the action of EF. We have used a tandem cell-based and protein-binding based screen of a 10,000 compound library as well as lead optimization to identify a lead (4-[4-(4-nitrophenyl)-thiazolylamino]-benzene-sulfonamide) that can block the interaction of EF with its cellular activator, calmodulin with 5 microM affinity and the minimal cell toxicity. In this application, we will combine chemical synthesis, cell-based assays, and in vitro assay to optimize the affinity of this sulfonamide compound to the low to mid-nM level. We will also use X-ray crystallography to determine the molecular structure of EF in complex with the optimized sulfonamide lead to address how this lead interrupts the binding of calmodulin to EF. We have found adefovir, a clinically approved anti-hepatitis B virus drug that can potently inhibit the activity of EF in tissue culture cells. Adefovir dipivoxil works to compete with the cellular substrate of EF, ATP to reduce the cAMP formation. We will also examine whether the optimized sulfonamide compound can work in concert with adefovir to achieve the greater inhibition of EF-intoxication. Success in our proposal will provide the blueprint to generate the effective EF inhibitors as an adjunct therapeutic against anthrax infection.
2001年与生物恐怖主义有关的炭疽表明,炭疽孢子可以成为一种有效的生物恐怖主义制剂,造成大规模的破坏和伤亡。如果炭疽孢子再次被使用,我们需要所有可能的治疗方法来保护受影响的人免受这种可怕的生物战剂的伤害。炭疽是由革兰氏阳性细菌——炭疽芽孢杆菌的生长和炭疽细菌分泌的毒素引起的。两种主要的炭疽毒素,水肿毒素(EdTx)和致死毒素(LeTx)改变细胞内信号。水肿因子(EF), EdTx的催化成分,具有钙调素激活腺苷酸环化酶活性,提高细胞内不受控制的cAMP水平。越来越多的证据表明EF是一个关键的毒力因子

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

WEI-JEN TANG其他文献

WEI-JEN TANG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('WEI-JEN TANG', 18)}}的其他基金

Integrative structural analysis of human insulin degrading enzyme
人胰岛素降解酶的整体结构分析
  • 批准号:
    10684300
  • 财政年份:
    2017
  • 资助金额:
    $ 44.32万
  • 项目类别:
Integrative structural analysis of human insulin degrading enzyme
人胰岛素降解酶的整体结构分析
  • 批准号:
    10810459
  • 财政年份:
    2017
  • 资助金额:
    $ 44.32万
  • 项目类别:
Integrative structural analysis of human insulin degrading enzyme
人胰岛素降解酶的整体结构分析
  • 批准号:
    10490454
  • 财政年份:
    2017
  • 资助金额:
    $ 44.32万
  • 项目类别:
Integrative structural analysis of human insulin degrading enzyme
人胰岛素降解酶的整体结构分析
  • 批准号:
    10367488
  • 财政年份:
    2017
  • 资助金额:
    $ 44.32万
  • 项目类别:
ANALYZE THE COMPLEX PROTEIN ASSEMBLY USING SAXS
使用 SAXS 分析复杂的蛋白质组装
  • 批准号:
    8361305
  • 财政年份:
    2011
  • 资助金额:
    $ 44.32万
  • 项目类别:
SAXS OF THE COMPLEX OF ANTHRAX TOXINS AND HUMAN INSULIN DEGRADING ENZYME
炭疽毒素与人胰岛素降解酶复合物的SAXS
  • 批准号:
    8168652
  • 财政年份:
    2010
  • 资助金额:
    $ 44.32万
  • 项目类别:
Regulation and Catalysis of Human Insulin Degrading Enzyme
人胰岛素降解酶的调控与催化
  • 批准号:
    7898366
  • 财政年份:
    2009
  • 资助金额:
    $ 44.32万
  • 项目类别:
PRESEQUENCE PEPTIDASE IN NATIVE OR COMPLEXED WITH SUBSTRATES
天然或与底物复合的前序列肽酶
  • 批准号:
    7956813
  • 财政年份:
    2009
  • 资助金额:
    $ 44.32万
  • 项目类别:
INSULIN DEGRADING ENZYME IN COMPLEX WITH NATRIURETIC PEPTIDES
胰岛素降解酶与钠尿肽的复合物
  • 批准号:
    7956832
  • 财政年份:
    2009
  • 资助金额:
    $ 44.32万
  • 项目类别:
INSULIN DEGRADING ENZYME IN COMPLEX WITH THE NOVEL SUBSTRATES
胰岛素降解酶与新型底物的复合物
  • 批准号:
    7956828
  • 财政年份:
    2009
  • 资助金额:
    $ 44.32万
  • 项目类别:

相似国自然基金

以胆酸为载体的肝靶向阿德福韦前体药物的研究
  • 批准号:
    30772653
  • 批准年份:
    2007
  • 资助金额:
    35.0 万元
  • 项目类别:
    面上项目

相似海外基金

Activation of C/EBP-β by mitohormesis as a therapy for obesity
通过线粒体毒物兴奋作用激活 C/EBP-β 作为肥胖疗法
  • 批准号:
    10551885
  • 财政年份:
    2022
  • 资助金额:
    $ 44.32万
  • 项目类别:
Activation of C/EBP-β by mitohormesis as a therapy for obesity
通过线粒体毒物兴奋作用激活 C/EBP-β 作为肥胖疗法
  • 批准号:
    10369251
  • 财政年份:
    2022
  • 资助金额:
    $ 44.32万
  • 项目类别:
Regulation of the life cycle of HDV by the drug resistance mutations of HBV
乙型肝炎病毒耐药突变对丁型肝炎病毒生命周期的调控
  • 批准号:
    10456292
  • 财政年份:
    2021
  • 资助金额:
    $ 44.32万
  • 项目类别:
Biomarkers of Replication and Injury in HBV/HIV
HBV/HIV 复制和损伤的生物标志物
  • 批准号:
    10449351
  • 财政年份:
    2021
  • 资助金额:
    $ 44.32万
  • 项目类别:
Biomarkers of Replication and Injury in HBV/HIV
HBV/HIV 复制和损伤的生物标志物
  • 批准号:
    10326569
  • 财政年份:
    2021
  • 资助金额:
    $ 44.32万
  • 项目类别:
Regulation of the life cycle of HDV by the drug resistance mutations of HBV
乙型肝炎病毒耐药突变对丁型肝炎病毒生命周期的调控
  • 批准号:
    10285584
  • 财政年份:
    2021
  • 资助金额:
    $ 44.32万
  • 项目类别:
Development of pharmacokinetic assays utilizing an organ-on-chip model of the human kidney proximal tubule
利用人肾近端小管的器官芯片模型开发药代动力学测定
  • 批准号:
    10210318
  • 财政年份:
    2019
  • 资助金额:
    $ 44.32万
  • 项目类别:
Development of pharmacokinetic assays utilizing an organ-on-chip model of the human kidney proximal tubule
利用人肾近端小管的器官芯片模型开发药代动力学测定
  • 批准号:
    10173393
  • 财政年份:
    2019
  • 资助金额:
    $ 44.32万
  • 项目类别:
Renal Disposition in NASH
NASH 中的肾脏配置
  • 批准号:
    10331779
  • 财政年份:
    2019
  • 资助金额:
    $ 44.32万
  • 项目类别:
Renal Disposition in NASH
NASH 中的肾脏配置
  • 批准号:
    10094060
  • 财政年份:
    2019
  • 资助金额:
    $ 44.32万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了